Table 7.

Change from baseline in WHO FC

Timepoint	Full analysis set		Switched patientsa		Treatment-naïve patients
	n	Improved/stabilized/ worsened (%)	n	Improved/stabilized/ worsened (%)	n	Improved/stabilized/ worsened (%)
Dose-adjustment phase
Week 2	293	8/90/2	82	5/94/1	211	9/89/3
Week 4	292	13/84/2	81	12/86/1	211	14/83/3
Week 6	289	15/83/2	79	11/87/1	210	16/82/2
Week 8	284	19/79/2	78	17/82/1	206	20/78/2
Maintenance phase
Week 12	264	22/73/5	70	21/76/3	194	22/72/6
Week 24	208	25/70/5	52	17/79/4	156	28/67/5
Week 36	162	30/69/1	43	23/77/0	119	32/66/2
Week 48	114	29/69/2	28	21/79/0	86	31/66/2

ERA endothelin receptor antagonist, PDE5 phosphodiesterase type 5, WHO FC World Health Organization functional class

^aPatients who previously received an ERA, prostacyclin, and/or PDE5 inhibitor, and who stopped this treatment before starting riociguat